Intelligence Platform
Patents
Browse 218 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.
US 8426458
Hepatitis C Virus inhibitors
granted patentUS 8420686
Linked diimidazole antivirals
granted patentUS 8420596
Macrocyclic hepatitis C serine protease inhibitors
granted patentUS 8383785
Anti-bacterial activity of 9-hydroxy derivatives of 6,11-bicyclolides
granted patentUS 8383583
Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
granted patentUS 8377872
Cyclic P3 tripeptide hepatitis C serine protease inhibitors
granted patentUS 8372802
Fluorinated macrocyclic compounds as hepatitis C virus inhibitors
granted patentUS 8367618
Cyclosporin analogues for preventing or treating hepatitis C infection
granted patentUS 8367053
Cyclosporin analogues
granted patentUS 8361958
Oximyl HCV serine protease inhibitors
granted patentUS 8354383
6,11-bridged biaryl macrolides
granted patentUS 8349312
Proline substituted cyclosporin analogues
granted patentUS 8324155
Quinoxaline-containing compounds as hepatitis C virus inhibitors
granted patentUS 8314135
Linked dibenzimidazole antivirals
granted patentUS 8304385
Macrocyclic tetrazolyl hepatitis C serine protease inhibitors
granted patentUS 8283309
Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors
granted patentUS 8273709
Triazole-containing macrocyclic HCV serine protease inhibitors
granted patentUS 8268777
Oximyl macrocyclic derivatives
granted patentUS 8268776
Macrocylic oximyl hepatitis C protease inhibitors
granted patentUS 8263549
C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
granted patentUS 8242156
Linked dibenzimidazole derivatives
granted patentUS 8236807
Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
granted patentUS 8221737
Hepatitis C virus inhibitors
granted patentUS 8222203
Macrocyclic oximyl hepatitis C serine protease inhibitors
granted